<--GAT-->
Clinical Topics

Side-effects Differ Between Radiation Therapies for Prostate Cancer

by U.S. Medicine

September 9, 2018

NASHVILLE, TN—A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.

With results published in the International Journal of Radiology, Oncology, Biology & Physics, the prospective, population-based Comparative Effectiveness Analysis of Surgery and Radiation study enrolled men with localized prostate cancer in 2011 to 2012.1

A study team led by Vanderbilt University Medical School researchers and including participation from the Nashville VAMC used the 26-item Expanded Prostate Cancer Index Composite to measure patient-reported disease-specific function at baseline and at 6, 12 and 36 months. In that measure, higher domain scores indicate better function.

The trial defined minimal clinically important difference as 6 for urinary incontinence, 5 for urinary irritative function, 4 for bowel function, 12 for sexual function and 4 for hormonal function.

Overall, 578 men received EBRT and 109 received EB-LDR. Among participants, median patient age was 69 years, and 70% had intermediate- or high-risk disease. Although men in the EB-LDR group were younger (and less likely to receive androgen deprivation therapy, baseline urinary, bowel, sexual, and hormonal function was similar between treatment groups, study authors reported.

Results indicated that, on multivariable analyses, men receiving EB-LDR reported worse urinary irritative function at six months (adjusted mean difference [AMD] -14.4, P <0.001), 12 months (AMD -12.9, P<0.001) and 36 months (AMD -4.7, P = 0.034) than men receiving EBRT.

In addition, at 12 months, men receiving EB-LDR reported worse bowel function (AMD -5.8, P = 0.002), but those differences were not documented at 36 months. No significant differences in sexual or hormone function were detected between the treatment groups, however.

“Men treated with EB-LDR report worse bowel function at one year and worse urinary irritative function through three years compared with men treated with EBRT alone,” study authors concluded. “These side effect profiles should be discussed with patients when considering EB-LDR versus EBRT treatment.”

1. Lee DJ, Barocas DA, Zhao Z, Huang LC, et. Al. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):116-126. doi:10.1016/j.ijrobp.2018.05.043. Epub 2018 Jun 1. PubMed PMID: 30102188.


Comments are closed here.


Related Articles

HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation which also pointed out that, although prostate cancer is prevalent in aging... View Article

VA Study Finds No Link Between ADT, Dementia

LA JOLLA, CA—Research has been conflicting on whether androgen deprivation therapy is related to dementia. A research letter in JAMA Oncology pointed out that two studies reported a strong statistically significant association between ADT and... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article

Oncology

Response of Veterans to PD-1 Checkpoint Inhibitors

RENO, NV—The clinical outcomes and the incidence of adverse events for programmed death-1 checkpoint inhibitors in cancer patients at a VA clinic were different from the data that have been published, according to a new... View Article

Oncology

Surgical Staging Often Inadequate for Gallbladder Cancer

Guidelines frequently aren’t followed when it comes to radical cholecystectomy with regional lymphadenectomy for patients with T1b gallbladder cancer.

Oncology

Use of Hospice During Treatment Has Limited VA Use

Unlike in most private sector settings, veterans with advanced cancer can receive hospice care concurrently with treatments such as radiation and chemotherapy.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up